Genetic Ancestry-Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies.

ABSTRACT:

Importance

Although differences in the prevalence of key cancer-specific somatic mutations as a function of genetic ancestry among patients with cancer has been well-established, few studies have addressed the practical clinical implications of these differences for the growing number of biomarker-driven treatments.

Objective

To determine if the approval of precision oncology therapies has benefited patients with cancer from various ancestral backgrounds equally over time.

Design, setting, and participants

A retrospective analysis of samples from patients with solid cancers who underwent clinical sequencing using the integrated mutation profiling of actionable cancer targets (MSK-IMPACT) assay between January 2014 and December 2022 was carried out. The annual fraction

SUBMITTER: Arora K 

PROVIDER: S-EPMC11926650 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature